Background: Prostate cancer is a common disease in men over 50 years. Only early detection by screening can guarantee a favourable outcome. Objective: The objective of the study is to report on the practice of prostate cancer screening by general practitioners in Lomé. Material and Method: This was a practice survey. A questionnaire administered to general practitioners allowed to examine the following parameters: the practitioner’s years of practice, the screening criteria, the screening tools and the factors motivating the request for urological advice. The data were analysed using the software Epi info 7.1.5. The P value was considered significant below 0.05. Results: One hundred and eighty (180) physicians average-aged 29 were administered among whom one hundred and fifty-seven (157) males and twenty-three (23) females. The average duration of the medical practice was 35.2 months (6 months - 204 months). The screening criteria were age (47.2%), family history of cancer (17.8%), and age over 50 years associated with symptoms of the low urinary tract (35%). The practitioner’s experience did not affect these criteria (p = 0.12). The screening tools were the digital rectal examination (DRE) associated with prostate specific antigen (PSA) assay (20.5%), PSA alone (29.5%), DRE alone (6.6%), suprapubic ultrasound (32.3%) and endorectal ultrasound (11.1%). The choice of the screening tool was related to the practitioner’s experience (p = 0.03). The determining factor for a urological consultation was a high PSA (>4 ng/ml) independent of the DRE. Conclusion: Prostate cancer screening is largely done by general practitioners in Lomé. However, the use of some criteria and tools for the screening is not optimal.
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30. https://doi.org/10.3322/caac.21387
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E38. https://doi.org/10.1002/ijc.29210 6.
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. (2009) Screening and Prostate-Cancer Mortality in a Randomized European Study. The New England Journal of Medicine, 360, 1320-1328. https://doi.org/10.1056/NEJMoa0810084
Mongiat-Artus, P. and Teillac, P. (2006) Dépistage du cancer de la prostate: Synthèse. Annales d’Urologie, 40, 106-110. https://doi.org/10.1016/j.anuro.2006.01.009
Perrin, P. (2008) Dépistage du cancer de la prostate: Les arguments 《contre》. Médecine Nucléaire, 32, 41-45. https://doi.org/10.1016/j.mednuc.2007.11.005
Cassell, A., Yunusa, B., Jalloh, M., Mbodji, M.M., Diallo, A., Ndoye, M., et al. (2019) A Review of Localized Prostate Cancer: An African Perspective. World Journal of Oncology, 10, 162-168. https://doi.org/10.14740/wjon1221
Ferlay, J.E.M., Lam, F., Colombet, M., Mery, L., Pineros, M., Znaor, A., Soerjomataram, I., et al. (2019) Global Cancer Observatory: Cancer Tomorrow. International Agency for Research on Cancer, Lyon. https://gco.iarc.fr/tomorrow
Tengué, K., Kpatcha, T.M., Botcho, G., Leloua, E., Amavi, A.K., Sikpa, K., Sewa, E., Anoukoum, T., Amegbor, K. and Dosseh, E. (2016) Profilépidémiologique, diagnostique, thérapeutiqueetévolutif du cancer de la prostate au Togo. African Journal of Urology, 22, 76-82. https://doi.org/10.1016/j.afju.2015.06.006
Labbé, D.P., Zadra, G., Yang, M., Reyes, J.M., Lin, C.Y., Cacciatore, S., et al. (2019) High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program. Nature Communications, 10, Article No. 4358. https://doi.org/10.1038/s41467-019-12298-z
Mottet, N., Comford, P., Van der Bergh, R.C.N., Briers, E., De Santis, M., Gillesen, S., Grummet, J., Henry, A.M., Van der Kwast, T.H., Lam, T.B., Masson, M.D., O’Hanlon, S., Oprea-Lager, D.E., Ploussard, G., Van der Poel, H.G., Rouvière, O., Schoots, I.G., Tilki, D., Wiegel, T., Van den Broeck, T., Cumberbatch, M., Farolfi, A., Fossati, N., Gandaglia, G., Grivas, N., Lardas, M., Liew, M., Moris, L. and Willemse, P.-P.M. (2021) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer in European Association of Urology Pocket Guideline. 2021 Edition, European Association of Urology (EAU), Arnhem, 74-75.
Kupelian, P., Klein, E., Witte, J., Kuppelian, V. and Suh, J. (1997) Familial Prostate Cancer: A Different Disease? Journal of Urology, 158, 2197-2201. https://doi.org/10.1016/S0022-5347(01)68194-1
Westerman, M.E., Gershman, B., Karnes, R.J., Thompson, R.H., Rangel, L. and Boorjian, S.A. (2015) Impact of a Family History of Prostate Cancer on Clinicopathologic Outcomes and Survival Following Radical Prostatectomy. World Journal of Urology, 8, 1115-1122. https://doi.org/10.1007/s00345-015-1738-6
Jansson, K.F., Akre, O., Garmo, H., Bill-Axelson, A., Adolfsson, J., Stattin, P., et al. (2012) Concordance of Tumor Differentiation among Brothers with Prostate Cancer. European Urology, 62, 656-661. https://doi.org/10.1016/j.eururo.2012.02.032
Brandt, A., Bermejo, J.L., Sundquist, J. and Hemminki, K. (2010) Age-specific Risk of Incident Prostate Cancer and Risk of Death from Prostate Cancer Defined by the Number of Affected Family Members. European Urology, 58, 275-280. https://doi.org/10.1016/j.eururo.2010.02.002
Kamangar, F., Dores, G.M. and Anderson, W.F. (2006) Patterns of Cancer Incidence, Mortality, and Prevalence across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. Journal of Clinical Oncology, 24, 2137-2150. https://doi.org/10.1200/JCO.2005.05.2308
Chornokur, G., Dalton, K., Borysova, M.E. and Kumar, N.B. (2011) Disparities at Presentation, Diagnosis, Treatment, and Survival in African American Men, Affected by Prostate Cancer. Prostate, 71, 985-97. https://doi.org/10.1002/pros.21314
Karami, S., Young, H.A. and Henson, D.E. (2007) Earlier Age at Diagnosis: Another Dimension in Cancer Disparity? Cancer Detection and Prevention, 31, 29-34. https://doi.org/10.1016/j.cdp.2006.11.004
Naji, L., Randhawa, H., Sohani, Z., Dennis, B., Lautenbach, D., Kavanagh, O., et al. (2018) Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. The Annals of Family Medicine, 16, 149-154. https://doi.org/10.1370/afm.2205
Richie, J.P., Catalona, W.J., Ahmann, F.R., Hudson, M.A., Scardino, P.T., Flanigan, R.C., et al. (1993) Effect of Patient Age on Early Detection of Prostate Cancer with Serum Prostate Specific Antigen and Digital Rectal Examination. Urology, 42, 365-374. https://doi.org/10.1016/0090-4295(93)90359-I
Stormont, T.J., Farrow, G.M., Myers, R.P., Blute, M.L., Zincke, H., Wilson, T.M. and Oesterling, J.E. (1993) Clinical Stage BO or T1c Prostate Cancer: Nonpalpable Disease Identified by Elevated Serum Prostate-Specific Antigen Concentration. Urology, 41, 3-8. https://doi.org/10.1016/0090-4295(93)90233-Z
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Zappa, M., Nelen, V., et al. (2014) Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up. Lancet, 384, 2027-2035. https://doi.org/10.1016/S0140-6736(14)60525-0
Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. (2012) Prostate-Cancer Mortality at 11 Years of Follow-up. The New England Journal of Medicine, 366, 981-990. https://doi.org/10.1056/NEJMoa1113135
Carvalhal, G.F., Smith, D.S., Mager, D.E., Ramos, C. and Catalona, W.J. (1999) Digital Rectal Examination for Detecting Prostate Cancer at Prostate Specific Antigen Levels of 4 ng./ml. or Less. Journal of Urology, 161, 835-839. https://doi.org/10.1016/S0022-5347(01)61785-3
Okotie, O.T., Roehl, K.A., Han, M., Loeb, S., Gashti, S.N. and Catalona, W.J. (2007) Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only. Urology, 70, 1117-1120. https://doi.org/10.1016/j.urology.2007.07.019
Gosselaar, C., Roobol, M.J., Roemeling, S. and Schröder, S.H. (2008) The Role of the Digital Rectal Examination in Subsequent Screening Visits in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. European Urology, 54, 581-588. https://doi.org/10.1016/j.eururo.2008.03.104
Thompson, I.M., Pauler, D.K., Goodman, P.J., Tangen, C.M., Lucia, M.S., Parnes, H.L., et al. (2004) Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤ 4.0 ng per milliliter. The New England Journal of Medicine, 350, 2239-2246. https://doi.org/10.1056/NEJMoa031918